Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.32 CAD
Change Today -0.005 / -1.54%
Volume 389.8K
As of 3:59 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

theralase technologies inc (TLT) Snapshot

Open
C$0.33
Previous Close
C$0.33
Day High
C$0.33
Day Low
C$0.32
52 Week High
12/23/14 - C$0.78
52 Week Low
05/15/14 - C$0.21
Market Cap
33.5M
Average Volume 10 Days
326.8K
EPS TTM
C$-0.05
Shares Outstanding
104.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERALASE TECHNOLOGIES INC (TLT)

Related News

No related news articles were found.

theralase technologies inc (TLT) Related Businessweek News

No Related Businessweek News Found

theralase technologies inc (TLT) Details

Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in bio-stimulative and bio-destructive clinical applications. The company engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of chronic pain, neural muscular-skeletal conditions, and wound healing. It is also involved in the commercialization of the patented TLC-3000 photo dynamic compound technology through pre-clinical scientific research, clinical trials, and technology development in the treatment of cancers for oncological applications and in the destruction of bacteria, viruses, and microbial pathogens; and research and development activities. The company sells its products to licensed healthcare practitioners, such as medical doctors, chiropractors, physical therapists, and athletic therapists in Canada, the United States, and internationally. Theralase Technologies Inc. is headquartered in Toronto, Canada.

theralase technologies inc (TLT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$150.0K
Chief Financial Officer
Total Annual Compensation: C$115.0K
Compensation as of Fiscal Year 2013.

theralase technologies inc (TLT) Key Developments

Theralase Technologies Inc. Reports Earnings Results for the Year Ended December 31, 2014

Theralase Technologies Inc. reported earnings results for the year ended December 31, 2014. For the year, the company’s total revenue increased 15% to CAD 1,380,604 from CAD 1,203,620 year over year. The net loss for the year was CAD 2,587,542 compared to a net loss of CAD 1,152,209 a year ago. The net loss is a reflection of the ongoing commitment of Theralase to invest in the next generation of therapeutic laser technology and anti-cancer treatment technology, partly funded from existing therapeutic laser sales.

Theralase Technologies Inc. Manufactures First Pre-Commercial Batch of Lead Anti-Cancer Drug

Theralase Technologies Inc. announced that it has successfully manufactured the first pre- commercial batch of its lead anti-cancer Photo Dynamic Compound (PDC), TLD-1433, one of a new generation of unique light-activated anti-cancer compounds, specifically developed for the treatment of cancer. Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices (GMP) standards. To achieve GMP standards, the normal process is a scale-up in production from a small quantity to validate the manufacturing process to larger pre-commercial quantities demonstrating manufacturing optimization and finally commercial quantities, produced under strict GMP standards, suitable for human use.

Theralase Technologies Inc. Partners with CiToxLAB Safety and Health Research Laboratories to Provide Toxicology and Safety Pharmacology for the Lead Anti-Cancer Photo Dynamic Compound (PDC), TLD-1433

Theralase Technologies Inc. announced that it has partnered with CiToxLAB Safety and Health Research Laboratories (CiToxLAB) to provide toxicology and safety pharmacology for the lead anti-cancer Photo Dynamic Compound (PDC), TLD-1433. In order to further identify the safe dosing range of TLD-1433 to be used in human clinical trials for Non Muscle Invasive Bladder Cancer (NMIBC) planned for later this year, CitoxLAB will study the effects that TLD-1433 has on biological systems, alone and when light activated and analyze any interactions that these effects may have on the functioning of normal biological processes. Theralase is currently in development of a platform of anti-cancer Photo Dynamic Therapy (PDT) technologies for the destruction of numerous cancers, commencing with the destruction of NMIBC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLT:CN C$0.32 CAD -0.005

TLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLT.
View Industry Companies
 

Industry Analysis

TLT

Industry Average

Valuation TLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.8x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERALASE TECHNOLOGIES INC, please visit www.theralase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.